Skip to main content
Top
Published in: Angiogenesis 3/2008

01-09-2008 | Original Paper

VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing’s sarcoma vasculature

Authors: Krishna Reddy, Ying Cao, Zhichao Zhou, Ling Yu, Shu-Fang Jia, Eugenie S. Kleinerman

Published in: Angiogenesis | Issue 3/2008

Login to get access

Abstract

We previously demonstrated that bone marrow (BM) cells migrate to Ewing’s tumors and differentiate into endothelial cells within the tumor vasculature. Recent evidence suggests that the roles of BM cells in tumors are more diverse. We investigated whether non-endothelial cell types critical for tumor vessel development are also derived from migrated BM cells. We utilized BM transplantation with GFP+ transgenic mice as BM donors and nude mice as recipients to track the fate of migrated BM cells. After engraftment, we injected recipient mice either subcutaneously or intramuscularly with Ewing’s sarcoma cells. We labeled functional tumor vessels using intravascular perfusion staining with tomato lectin. We assessed BM cell recruitment/differentiation within the tumor microenvironment using immunohistochemistry. Ewing’s tumors contained BM-derived cells that had differentiated into endothelial cells lining perfused tumor vessels. A substantial fraction of recruited BM cells also resided in the vessel vicinity and expressed desmin and PDGFR-β, indicating smooth muscle cell differentiation. In order to further characterize the role of stem/progenitor cells in Ewing’s sarcoma, we sorted Tie2 BM cells from Tie2-GFP transgenic mice and then injected them intravenously into Ewing’s tumor-bearing mice. Tie2 BM progenitors migrated to Ewing’s tumors and differentiated into Tie2+ cells occupying a perivascular residence and expressing α-smooth muscle actin, desmin and PDGFR-β, as well as VEGFR-2. We did not observe differentiation of Tie2 cells into Tie2+ perivascular cells in VEGF165-inhibited TC/siVEGF7-1 tumors. The differentiation of Tie2 BM cells into Tie2+ cells in parental but not VEGF165-inhibited tumors indicates that the tumor microenvironment may influence the differentiation pathway.
Literature
1.
go back to reference Bolontrade MF, Zhou RR, Kleinerman ES (2002) Vasculogenesis plays a role in the growth of Ewing’s sarcoma in vivo. Clin Cancer Res 8:3622–3627PubMed Bolontrade MF, Zhou RR, Kleinerman ES (2002) Vasculogenesis plays a role in the growth of Ewing’s sarcoma in vivo. Clin Cancer Res 8:3622–3627PubMed
2.
go back to reference Lee TH, Bolontrade MF, Worth LL, Guan H, Ellis LM, Kleinerman ES (2006) Production of VEGF165 by Ewing’s sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature. Int J Cancer 119:839–846PubMedCrossRef Lee TH, Bolontrade MF, Worth LL, Guan H, Ellis LM, Kleinerman ES (2006) Production of VEGF165 by Ewing’s sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature. Int J Cancer 119:839–846PubMedCrossRef
3.
go back to reference Guan H, Zhou Z, Wang H, Jia S-F, Liu W, Kleinerman ES (2005) A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing’s sarcoma growth in a xenograft mouse model. Clin Cancer Res 11:2662–2669PubMedCrossRef Guan H, Zhou Z, Wang H, Jia S-F, Liu W, Kleinerman ES (2005) A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing’s sarcoma growth in a xenograft mouse model. Clin Cancer Res 11:2662–2669PubMedCrossRef
4.
go back to reference Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194–1201PubMedCrossRef Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194–1201PubMedCrossRef
5.
go back to reference Dwenger A, Rosenthal F, Machein M, Waller C, Spyridonidis A (2004) Transplanted bone marrow cells preferentially home to the vessels of in situ generated murine tumors rather than of normal organs. Stem Cells 22:86–92PubMedCrossRef Dwenger A, Rosenthal F, Machein M, Waller C, Spyridonidis A (2004) Transplanted bone marrow cells preferentially home to the vessels of in situ generated murine tumors rather than of normal organs. Stem Cells 22:86–92PubMedCrossRef
6.
go back to reference Duda DG, Cohen KS, Kozin SV, Perentes JY, Fukumura D, Scadden DT, Jain RK (2006) Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood 107:2774–2776PubMedCrossRef Duda DG, Cohen KS, Kozin SV, Perentes JY, Fukumura D, Scadden DT, Jain RK (2006) Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood 107:2774–2776PubMedCrossRef
7.
go back to reference Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G (2005) PDGFRβ+ perivascular progenitor cells in tumors regulate pericyte differentiation and vascular survival. Nat Cell Biol 7:870–879PubMedCrossRef Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G (2005) PDGFRβ+ perivascular progenitor cells in tumors regulate pericyte differentiation and vascular survival. Nat Cell Biol 7:870–879PubMedCrossRef
8.
go back to reference Rajantie I, Ilmonen M, Alminaite A, Ozerdem U, Alitalo K, Salven P (2004) Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 104:2084–2086PubMedCrossRef Rajantie I, Ilmonen M, Alminaite A, Ozerdem U, Alitalo K, Salven P (2004) Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 104:2084–2086PubMedCrossRef
9.
go back to reference Lamagna C, Bergers G (2006) The bone marrow constitutes a reservoir of pericyte progenitors. J Leukoc Biol 80:677–681PubMedCrossRef Lamagna C, Bergers G (2006) The bone marrow constitutes a reservoir of pericyte progenitors. J Leukoc Biol 80:677–681PubMedCrossRef
10.
go back to reference De Palma M, Venneri MA, Roca C, Naldini L (2003) Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 9:789–795PubMedCrossRef De Palma M, Venneri MA, Roca C, Naldini L (2003) Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 9:789–795PubMedCrossRef
11.
go back to reference Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC (2004) Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409–421PubMedCrossRef Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC (2004) Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409–421PubMedCrossRef
12.
go back to reference Yotnda P, Onishi H, Heslop HE, Shayakhmetov D, Lieber A, Brenner M, Davis A (2001) Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther 8:930–937PubMedCrossRef Yotnda P, Onishi H, Heslop HE, Shayakhmetov D, Lieber A, Brenner M, Davis A (2001) Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther 8:930–937PubMedCrossRef
13.
go back to reference Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C (1999) Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126:3047–3055PubMed Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C (1999) Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126:3047–3055PubMed
14.
go back to reference Lindahl P, Johansson BR, Leveen P, Betsholtz C (1997) Pericyte loss, microaneurysm formation in PDGF-B-deficient mice. Science 277:242–245PubMedCrossRef Lindahl P, Johansson BR, Leveen P, Betsholtz C (1997) Pericyte loss, microaneurysm formation in PDGF-B-deficient mice. Science 277:242–245PubMedCrossRef
15.
go back to reference Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287–1295PubMed Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287–1295PubMed
16.
go back to reference De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, Naldini L (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8:211–226PubMedCrossRef De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, Naldini L (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8:211–226PubMedCrossRef
Metadata
Title
VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing’s sarcoma vasculature
Authors
Krishna Reddy
Ying Cao
Zhichao Zhou
Ling Yu
Shu-Fang Jia
Eugenie S. Kleinerman
Publication date
01-09-2008
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 3/2008
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-008-9109-1

Other articles of this Issue 3/2008

Angiogenesis 3/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine